Geo Capital Gestora de Recursos Ltd Acquires 7,539 Shares of Danaher Co. (NYSE:DHR)

Geo Capital Gestora de Recursos Ltd grew its holdings in shares of Danaher Co. (NYSE:DHR) by 160.5% during the fourth quarter, according to the company in its most recent disclosure with the SEC. The fund owned 12,235 shares of the conglomerate’s stock after buying an additional 7,539 shares during the quarter. Danaher accounts for about 3.1% of Geo Capital Gestora de Recursos Ltd’s investment portfolio, making the stock its 11th biggest position. Geo Capital Gestora de Recursos Ltd’s holdings in Danaher were worth $2,830,000 at the end of the most recent quarter.

A number of other hedge funds have also recently modified their holdings of DHR. Cape Investment Advisory Inc. purchased a new stake in shares of Danaher in the fourth quarter valued at approximately $25,000. BKM Wealth Management LLC purchased a new stake in shares of Danaher in the fourth quarter valued at approximately $27,000. Wetzel Investment Advisors Inc. purchased a new stake in shares of Danaher in the fourth quarter valued at approximately $29,000. Rakuten Securities Inc. purchased a new stake in shares of Danaher in the fourth quarter valued at approximately $36,000. Finally, Financial Connections Group Inc. purchased a new stake in shares of Danaher in the fourth quarter valued at approximately $41,000. Institutional investors own 79.05% of the company’s stock.

Wall Street Analyst Weigh In

DHR has been the subject of a number of research reports. Barclays boosted their price target on Danaher from $260.00 to $270.00 and gave the company an “equal weight” rating in a report on Wednesday, April 24th. Citigroup boosted their price target on Danaher from $280.00 to $290.00 and gave the company a “buy” rating in a report on Wednesday, April 24th. Bank of America boosted their price target on Danaher from $258.00 to $270.00 and gave the company a “neutral” rating in a report on Wednesday, April 24th. TD Cowen upped their target price on Danaher from $280.00 to $290.00 and gave the stock a “buy” rating in a report on Wednesday, April 24th. Finally, Robert W. Baird upped their target price on Danaher from $259.00 to $271.00 and gave the stock an “outperform” rating in a report on Wednesday, April 24th. Six analysts have rated the stock with a hold rating and ten have assigned a buy rating to the company. According to MarketBeat.com, Danaher has a consensus rating of “Moderate Buy” and an average price target of $269.29.

Danaher Stock Down 0.1 %

Shares of DHR stock traded down $0.16 during trading hours on Friday, reaching $254.85. 3,097,194 shares of the company’s stock were exchanged, compared to its average volume of 2,930,997. The stock’s 50 day moving average is $253.48 and its 200-day moving average is $244.30. The company has a market cap of $188.76 billion, a price-to-earnings ratio of 43.19, a P/E/G ratio of 3.90 and a beta of 0.85. The company has a current ratio of 1.85, a quick ratio of 1.51 and a debt-to-equity ratio of 0.31. Danaher Co. has a fifty-two week low of $182.09 and a fifty-two week high of $269.11.

Danaher (NYSE:DHR) last released its earnings results on Tuesday, April 23rd. The conglomerate reported $1.92 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.72 by $0.20. Danaher had a return on equity of 11.43% and a net margin of 16.78%. The firm had revenue of $5.80 billion for the quarter, compared to the consensus estimate of $5.62 billion. During the same period in the prior year, the firm earned $2.36 EPS. The firm’s revenue was down 2.6% on a year-over-year basis. Analysts predict that Danaher Co. will post 7.63 earnings per share for the current fiscal year.

Danaher Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Friday, July 26th. Investors of record on Friday, June 28th will be given a $0.27 dividend. This represents a $1.08 annualized dividend and a dividend yield of 0.42%. The ex-dividend date is Friday, June 28th. Danaher’s payout ratio is 18.31%.

Insider Activity at Danaher

In related news, CEO Rainer Blair sold 9,005 shares of the company’s stock in a transaction on Thursday, May 16th. The stock was sold at an average price of $265.00, for a total value of $2,386,325.00. Following the transaction, the chief executive officer now directly owns 106,990 shares of the company’s stock, valued at approximately $28,352,350. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. In other Danaher news, CEO Rainer Blair sold 9,005 shares of the stock in a transaction dated Thursday, May 16th. The stock was sold at an average price of $265.00, for a total transaction of $2,386,325.00. Following the sale, the chief executive officer now directly owns 106,990 shares of the company’s stock, valued at approximately $28,352,350. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Alan G. Spoon sold 708 shares of the stock in a transaction dated Thursday, May 2nd. The stock was sold at an average price of $243.58, for a total value of $172,454.64. Following the sale, the director now directly owns 116,202 shares in the company, valued at $28,304,483.16. The disclosure for this sale can be found here. Insiders have sold a total of 148,783 shares of company stock valued at $37,536,717 in the last ninety days. Company insiders own 11.10% of the company’s stock.

About Danaher

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.